<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947011</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00018441</org_study_id>
    <nct_id>NCT00947011</nct_id>
  </id_info>
  <brief_title>Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)</brief_title>
  <official_title>The Effect of Dipeptidyl Peptidase-4 Inhibition on GLP-1 Induced Insulin Secretion and Glucose Turnover During Mild Stable Hyperglycemia in Young and Old Normal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a
      naturally occurring hormone) on insulin release and to examine whether there is extra insulin
      release when GLP-1 is not allowed to be rapidly inactivated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the present proposal is to 1) examine the role of dipeptidyl peptidase (DPP-4)
      inhibition on insulin release during a hyperglycemic clamp while GLP-1 is being infused and,
      2) further elucidate the role of the metabolite of GLP-1, that is GLP-1 9-36 amide (GLP-1m).
      During stable and very reproducible elevated plasma glucose levels the effect of increased
      active incretin levels with DPP-4 inhibitors should result in increased plasma insulin
      levels. Therefore the aim of this protocol is to document whether plasma insulin levels are
      increased following GLP-1 infusion in the presence or absence of DPP-4 inhibitors.
      Additionally, the investigators have shown that some improvement in glucose homeostasis
      during GLP-1 administration is due in part to the metabolite of GLP-1, i.e. GLP-1 (9-36)
      amide (GLP-1m). Therefore, the investigators will also test the role of the latter by
      infusing GLP-1m when the volunteers are being treated with DPP-4 inhibitors.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left JHU
  </why_stopped>
  <start_date type="Actual">March 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Release Rate and Hepatic Glucose Release</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral Glucose Utilization and Peripheral Glucagon Release</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Glucose Homeostasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Januvia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet 100 mg once a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Januvia</intervention_name>
    <description>1 tablet 100 mg once a day</description>
    <arm_group_label>Januvia</arm_group_label>
    <other_name>Sitagliptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hct level of at least 34% for women and 36% for men

          -  Women of non-bearing potential and women of childbearing potential using adequate
             contraception

          -  Serum creatine level of less than 1.7 mg/dl

          -  Four groups:

               -  Age 21-45 (BMI between 18.50-24.99) &amp; (BMI between 30-35)

               -  Age greater than 65 years (BMI between 18.50-24.99) &amp; (BMI between 30-35)

        Exclusion Criteria:

          -  Pregnant and/or lactating females

          -  Women of childbearing potential not willing to use adequate contraception

          -  Hct below inclusion criteria

          -  Serum creatine level greater than 1.8 mg/dl

          -  Age less than 21 and age between 46-64

          -  Diabetes mellitus

          -  BMI less than 18 and BMI greater than 35
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariush Elahi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <results_first_submitted>May 1, 2017</results_first_submitted>
  <results_first_submitted_qc>June 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2017</results_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Januvia</keyword>
  <keyword>Sitagliptin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Although 12 participants were enrolled in this study, their assignment to a specific Arm/Group is unknown, as the PI has left the institution and no further data (if any) is available.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Januvia: 1 tablet 100 mg once a day
OR
Placebo comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study was terminated,PI left institution</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Although 12 participants were enrolled in this study, their assignment to a specific Arm/Group is unknown, as the PI has left the institution and no further data (if any) is available.</population>
      <group_list>
        <group group_id="B1">
          <title>All Particpants</title>
          <description>Januvia: 1 tablet 100 mg once a day
OR
Placebo: 1 tablet 100 mg once a day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=21 and &lt;=75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Release Rate and Hepatic Glucose Release</title>
        <time_frame>One year</time_frame>
        <population>Data was not collected for this outcome measure. The study was terminated. The P.I. left the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Januvia</title>
            <description>Januvia: 1 tablet 100 mg once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 tablet 100 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Release Rate and Hepatic Glucose Release</title>
          <population>Data was not collected for this outcome measure. The study was terminated. The P.I. left the institution.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Glucose Utilization and Peripheral Glucagon Release</title>
        <time_frame>one year</time_frame>
        <population>Data was not collected for this outcome measure. The study was terminated. The P.I. left the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Januvia</title>
            <description>Januvia: 1 tablet 100 mg once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 tablet 100 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Glucose Utilization and Peripheral Glucagon Release</title>
          <population>Data was not collected for this outcome measure. The study was terminated. The P.I. left the institution.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This study was prematurely terminated because the P.I. left the institution. The time frame for Adverse Event data (if collected) is unknown.</time_frame>
      <desc>This study was prematurely terminated because the P.I. left the institution. The data for Adverse Events, if collected, is unknown.</desc>
      <group_list>
        <group group_id="E1">
          <title>Januvia</title>
          <description>Januvia: 1 tablet 100 mg once a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 1 tablet 100 mg once a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johns Hopkins University Clinical Trials Program</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-6484</phone>
      <email>registerclinicaltrials@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

